Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies

被引：0

作者：

Nadal, R. ^{[1
]}

Mortazavi, A. ^{[2
]}

Stein, M. ^{[3
]}

Pal, S. K. ^{[4
]}

Davarpanah, N. ^{[1
]}

Parnes, H. L. ^{[1
]}

Ning, Y. M. ^{[1
]}

Cordes, L. M. ^{[1
]}

Lin, J. ^{[1
]}

Bagheri, M. ^{[5
]}

Linderberg, L. ^{[1
]}

Berniger, M. ^{[1
]}

Steinberg, S. M. ^{[6
]}

Moore, T. ^{[4
]}

Lancaster, T. ^{[2
]}

Aviles, M. ^{[3
]}

Costello, R. ^{[1
]}

Bottaro, D. P. ^{[1
]}

Dahut, W. L. ^{[1
]}

Apolo, A. B. ^{[1
]}

机构：

[1] NCI, Med Oncol, Ctr Canc Res, Bethesda, MD 20892 USA

[2] Ohio State Univ, Internal Med, James Canc Hosp, Columbus, OH 43210 USA

[3] Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA

[4] City Hope Natl Med Ctr, Med Oncol, Duarte, CA USA

[5] NCI, Ctr Canc Res, Radiol & Imaging Sci, Bethesda, MD 20892 USA

[6] NCI, Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD 20892 USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

846O

引用

页数：1

共 50 条

[31] Phase II trial of nivolumab (nivo) plus ipilimumab (ipi) in patients with SMARCB1-deficient kidney malignancies.
Msaouel, Pavlos
Slack-Tidwell, Rebecca
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[32] Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Girardi, Daniel M.
Niglio, Scot A.
Mortazavi, Amir
Nadal, Rosa
Lara, Primo
Pal, Sumanta K.
Saraiya, Biren
Cordes, Lisa
Ley, Lisa
Ortiz, Olena Sierra
Cadena, Jacqueline
Diaz, Carlos
Bagheri, Hadi
Redd, Bernadette
Steinberg, Seth M.
Costello, Rene
Chan, Keith S.
Lee, Min-Jung
Lee, Sunmin
Yu, Yunkai
Gurram, Sandeep
Chalfin, Heather J.
Valera, Vladimir
Figg, William D.
Merino, Maria
Toubaji, Antoun
Streicher, Howard
Wright, John J.
Sharon, Elad
Parnes, Howard L.
Ning, Yang-Min
Bottaro, Donald P.
Cao, Liang
Trepel, Jane B.
Apolo, Andrea B.
CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1353 - 1362
[33] Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) plus ipilimumab (ipi) plus external beam radiotherapy (RT) in patients with metastatic melanoma.
Postow, Michael A.
Knox, Susan Jane
Goldman, Debra
Panageas, Katherine
Halpenny, Darragh
McCabe, Danielle
Macri, Mary J.
Schwarzenberger, Paul
Ricciardi, Toni
Ryan, Aileen
Venhaus, Ralph Rudolph
Barker, Christopher Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[34] Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
Gul, Anita
Shah, Neil J.
Mantia, Charlene
Hammers, Hans J.
Ornstein, Moshe Chaim
McDermott, David F.
Atkins, Michael B.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[35] A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC)
Apolo, Andrea B.
Parnes, Howard L.
Francis, Deneise C.
Cordes, Lisa M.
Berninger, Marilise
Lamping, Elizabeth
Costello, Rene
Trepel, Jane B.
Merino, Maria J.
Folio, Les
Lindenberg, Maria Liza
Figg, William Douglas
Steinberg, Seth M.
Wright, John Joseph
Madan, Ravi Amrit
Ning, Yangmin M.
Gulley, James L.
Bottaro, Donald P.
Dahut, William L.
Agarwal, Piyush K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[36] A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC)
Apolo, Andrea Borghese
Parnes, Howard L.
Madan, Ravi Amrit
Gulley, James L.
Wright, John Joseph
Hoffman-Censits, Jean H.
Dawson, Nancy Ann
Trepel, Jane B.
Khadar, Kattie
Schlom, Jeffrey
Merino, Maria
Raffeld, Mark
Steinberg, Seth M.
Choyke, Peter L.
Lindenberg, Maria Liza
Folio, Les
Agarwal, Piyush K.
Figg, William Douglas
Bottaro, Donald P.
Dahut, William L.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[37] A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)
Nadal, R.
Parnes, H. L.
Francis, D. C.
Cordes, L. M.
Berninger, M.
Costello, R.
Folio, L.
Linderberg, M.
Machado, L.
Steinberg, S. M.
Wright, J. J.
Ning, Y. M.
Bottaro, D. P.
Dahut, W. L.
Apolo, A. B.
ANNALS OF ONCOLOGY, 2016, 27
[38] Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Koshkin, V. S.
Barthelemy, P.
Gravis, G.
Goodman, O.
Duran, I.
Girones Sarrio, R.
Hwang, C.
Garcia-Donas, J.
Morales Barrera, R.
Zanetta, S.
Chisamore, M.
Liu, M.
Gil, M.
Tomlinson, G.
Elsayed, H.
Loriot, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S1136 - S1137
[39] Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors
Apolo, Andrea B.
Girardi, Daniel M.
Niglio, Scot A.
Nadal, Rosa
Kydd, Andre R.
Simon, Nicholas
Ley, Lisa
Cordes, Lisa M.
Chandran, Elias
Steinberg, Seth M.
Lee, Sunmin
Lee, Min-Jung
Rastogi, Shraddha
Sato, Nahoko
Cao, Liang
Banday, A. Rouf
Boudjadi, Salah
Merino, Maria J.
Toubaji, Antoun
Akbulut, Dilara
Redd, Bernadette
Bagheri, Hadi
Costello, Rene
Gurram, Sandeep
Agarwal, Piyush K.
Chalfin, Heather J.
Valera, Vladimir
Streicher, Howard
Wright, John Joseph
Sharon, Elad
Figg, William D.
Parnes, Howard L.
Gulley, James L.
Saraiya, Biren
Pal, Sumanta K.
Quinn, David
Stein, Mark N.
Lara, Primo N.
Bottaro, Donald P.
Mortazavi, Amir
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (25)
[40] Nivolumab (NIVO) plus /- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) with advanced treatment-naive or -refractory basal cell carcinoma (BCC)
Schenk, K. M.
Deutsch, J. S.
Schollenberger, M. D.
Sharfman, W. H.
Brothers, P. N.
Pons, A.
Scott, J. F.
Bibee, K.
Taube, J. M.
Topalian, S. L.
Lipson, E. J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S922 - S923

← 1 2 3 4 5 →